Topical Use of Rapamycin in Herpetic Stromal Keratitis

REFERENCES

• Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20(1):1–13.
   PubMed Web of Science ®Google Scholar
• Gaskell R, Dawson S, Radford A, Thiry E. Feline herpesvirus. Vet Res. 2007;38(2):337–354.
   PubMed Web of Science ®Google Scholar
• Nasisse MP, English RV, Tompkins MB, Guy JS, Sussman W. Immunologic, histologic, and virologic features of herpesvirus-induced stromal keratitis in cats. Am J Vet Res. 1995;56(1):51–55.
   PubMed Web of Science ®Google Scholar
• Biswas PS, Rouse BT. Early events in HSV keratitis—setting the stage for a blinding disease. Microbes Infect. 2005;7(4):799–810.
   PubMed Web of Science ®Google Scholar
• Xia L, Zhang S, Zhou J, Li Y. A crucial role for B and T lymphocyte attenuator in preventing the development of CD4+ T cell-mediated herpetic stromal keratitis. Mol Vis. 2010;16:2071–2083.
   PubMed Web of Science ®Google Scholar
• Hosseini H, Khalili MR. Therapeutic potential of bevacizumab (Avastin) in herpetic stromal keratitis (HSK). Med Hypotheses. 2007;69(3):568–570.
   PubMed Web of Science ®Google Scholar
• Duan R, Remeijer L, van Dun JM, Osterhaus AD, Verjans GM. Granulocyte macrophage colony-stimulating factor expression in human herpetic stromal keratitis: implications for the role of neutrophils in HSK. Invest Ophthalmol Vis Sci. 2007;48(1):277–284.
   PubMed Web of Science ®Google Scholar
• Banerjee K, Biswas PS, Kim B, Lee S, Rouse BT. CXCR2-/- mice show enhanced susceptibility to herpetic stromal keratitis: a role for IL-6-induced neovascularization. J Immunol. 2004;172(2):1237–1245.
   PubMed Web of Science ®Google Scholar
• Bauer D, Mrzyk S, van Rooijen N, Steuhl KP, Heiligenhaus A. Macrophage-depletion influences the course of murine HSV-1 keratitis. Curr Eye Res. 2000;20(1):45–53.
   PubMed Web of Science ®Google Scholar
• Carr DJ, Tomanek L. Herpes simplex virus and the chemokines that mediate the inflammation. Curr Top Microbiol Immunol. 2006;303:47–65.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Bauer D, Zheng M, Mrzyk S, Steuhl KP. CD4+ T-cell type 1 and type 2 cytokines in the HSV-1 infected cornea. Graefes Arch Clin Exp Ophthalmol. 1999;237(5):399–406.
   PubMed Web of Science ®Google Scholar
• Shimeld C, Whiteland JL, Nicholls SM, Easty DL, Hill TJ. Immune cell infiltration in corneas of mice with recurrent herpes simplex virus disease. J Gen Virol. 1996;77 (Pt 5):977–985.
   PubMedGoogle Scholar
• Andrew SE. Ocular manifestations of feline herpesvirus. J Feline Med Surg. 2001;3(1):9–16.
   PubMedGoogle Scholar
• Wagner EK, Bloom DC. Experimental investigation of herpes simplex virus latency. Clin Microbiol Rev. 1997;10(3):419–443.
   PubMed Web of Science ®Google Scholar
• Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic Eye Disease Study: a controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994;101(12):1883–1895; discussion 1895–1896.
   Web of Science ®Google Scholar
• Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000;11(6):478–483.
   PubMedGoogle Scholar
• Mayman CI, Miller D, Tijerina ML. In vitro production of steroid cataract in bovine lens, part II: measurement of sodium-potassium adenosine triphosphatase activity. Acta Ophthalmol (Copenh). 1979;57(6):1107–1116.
   PubMed Web of Science ®Google Scholar
• Shi W, Chen M, Xie L. Amniotic membrane transplantation combined with antiviral and steroid therapy for herpes necrotizing stromal keratitis. Ophthalmology. 2007;114(8):1476–1481.
   PubMed Web of Science ®Google Scholar
• Underwood JL, Murphy CG, Chen J, et al. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol. 1999;277(2 Pt 1):C330–C342.
   PubMedGoogle Scholar
• Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol. 1986;31(2):102–110.
   PubMed Web of Science ®Google Scholar
• Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A: background, immunology, and pharmacology. Cornea. 1990;9(3):184–195.
   PubMed Web of Science ®Google Scholar
• Noguera A, Massó J, Soy D, Codina C, Ribas J. Sirolimus: una nueva alternativa en el tratamiento inmunosupresor. Farm Hosp. 2002;26(2):96–105.
   Google Scholar
• Shi W, Gao H, Xie L, Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci. 2006;47(8):3339–3344.
   PubMed Web of Science ®Google Scholar
• Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol. 2006;141(4):771–772.
   PubMed Web of Science ®Google Scholar
• Yoon KC, Heo H, Kang IS, et al. Effect of topical cyclosporin A on herpetic stromal keratitis in a mouse model. Cornea. 2008;27(4):454–460.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci. 2005;46(2):454–460.
   PubMed Web of Science ®Google Scholar
• Olsen TW, Benegas NM, Joplin AC, Evangelista T, Mindrup EA, Holland EJ. Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 1994;112(11):1471–1475.
   PubMedGoogle Scholar
• Pepose JS, Holland GN, Wilhelmus KR. Ocular Infection & Immunity. St. Louis: Mosby; 1996.
   Google Scholar
• Banerjee K, Deshpande S, Zheng M, Kumaraguru U, Schoenberger SP, Rouse BT. Herpetic stromal keratitis in the absence of viral antigen recognition. Cell Immunol. 2002;219(2):108–118.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Kim JC. Inhibition of corneal neovascularization by rapamycin. Exp Mol Med. 2006;38(2):173–179.
   PubMed Web of Science ®Google Scholar
• Blei F, Wilson EL, Mignatti P, Rifkin DB. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol. 1993;155(3):568–578.
   PubMed Web of Science ®Google Scholar
• Murata M, Shimizu S, Horiuchi S, Taira M. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2006;244(2):205–209.
   PubMed Web of Science ®Google Scholar
• Quesada AJ, Redondo JM. [Ca++/calcineurin/NFAT signaling in endothelial activation and angiogenesis: effects od cyclosporin A]. Nefrologia. 2003;23 (Suppl 3):44–48.
   PubMedGoogle Scholar
• Gomez del Arco P, Martinez-Martinez S, Maldonado JL, Ortega-Perez I, Redondo JM. A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp. J Biol Chem. 2000;275(18):13872–13878.
   PubMed Web of Science ®Google Scholar
• Graef IA, Chen F, Chen L, Kuo A, Crabtree GR. Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell. 2001;105(7):863–875.
   PubMed Web of Science ®Google Scholar
• Deshpande S, Zheng M, Lee S, et al. Bystander activation involving T lymphocytes in herpetic stromal keratitis. J Immunol. 2001;167(5):2902–2910.
   PubMed Web of Science ®Google Scholar
• Reis F, Parada B, Teixeira de Lemos E, et al. Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine. Transplant Proc. 2009;41(3):868–873.
   PubMed Web of Science ®Google Scholar
• Stanojlovic S, Schlickeiser S, Appelt C, et al. Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1447–1456.
   PubMedGoogle Scholar